Comprehensive medication guide to Palforzia 3 mg including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With commercial insurance, out-of-pocket cost for Palforzia varies by plan tier, deductible, and copay assistance eligibility. Prior authorization is required by all major insurers (Cigna, UHC, Aetna, BCBS). With the manufacturer copay assistance program active, some patients have paid minimal copays; contact the Palforzia Pathway Hub at 1-844-PALFORZ for current program status during the wind-down.
Estimated Cash Pricing
Palforzia costs approximately $654–$770 per month for up-dosing packs (including the 3 mg level) with a GoodRx coupon; the 300 mg maintenance sachet ranges from $683 to over $1,400 at retail. List price is approximately $890/month. Given the July 2026 discontinuation, cash-pay pricing may vary widely as remaining inventory is distributed.
Medfinder Findability Score
20/100
On this page
Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp) was the first and only FDA-approved oral immunotherapy (OIT) for peanut allergy. Approved in January 2020 for children ages 4 through 17 — and later expanded to toddlers ages 1 through 3 — it represented a landmark advancement in food allergy treatment. The drug is manufactured from defatted, roasted peanut flour and packaged in precisely measured capsules and sachets.
The 3 mg dose refers to the starting level of the Up-Dosing phase — the first maintenance home dose following the Initial Dose Escalation clinic day. Treatment progresses through 12 up-dosing levels over approximately six months before reaching the 300 mg maintenance phase.
Important 2026 update: Stallergenes Greer is voluntarily discontinuing all commercialization of Palforzia as of July 31, 2026 — not for safety or efficacy reasons, but due to commercial challenges related to the REMS program requirements. No new patients are being started on Palforzia. Patients currently on therapy should contact the Palforzia Pathway Hub (1-844-PALFORZ) and their allergist immediately.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Palforzia works through oral immunotherapy (OIT): deliberately exposing the immune system to the very allergen it overreacts to — peanut protein — in gradually increasing doses over time. In people with peanut allergy, the immune system has produced IgE antibodies tuned to react to peanut proteins (Ara h 1, Ara h 2, and Ara h 6). These IgE antibodies coat immune cells called mast cells and basophils, which release inflammatory chemicals upon peanut exposure — causing allergic reactions.
Repeated, low-dose peanut protein exposure via Palforzia retrains the immune system through multiple mechanisms: mast cell and basophil desensitization (raising the reaction threshold), regulatory T-cell induction (immune braking), and increased IgG4 blocking antibody production (intercepting peanut proteins before they trigger mast cells). Together, these changes mean that small accidental peanut exposures are less likely to trigger a severe or life-threatening reaction.
Palforzia induces desensitization — not a permanent cure. Ongoing daily dosing is required to maintain the achieved tolerance level. In the PALISADE pivotal trial, 67% of treated patients ages 4-17 could tolerate at least 600 mg of peanut protein without dose-limiting symptoms after completing the treatment protocol — roughly equivalent to two peanuts.
0.5 mg — capsule
Level A — Initial Dose Escalation only
1 mg — capsule
Level B — Initial Dose Escalation and Up-Dosing Level 1 (3 mg daily)
3 mg — capsule (3x 1mg)
Up-Dosing Level 1 — starting daily home dose
6 mg — capsule
Level E — Initial Dose Escalation (ages 4-17) and Up-Dosing Level 2
10 mg — capsule
Up-Dosing Level 3 — daily home dose
20 mg — capsule
Up-Dosing Levels 4-5
100 mg — capsule
Up-Dosing Levels 6-11
300 mg — sachet
Maintenance Phase — daily long-term dose (~1 peanut equivalent)
Palforzia has always been difficult to find compared to standard retail medications, because it was only dispensed through REMS-certified specialty pharmacies and enrolled healthcare settings — not standard retail pharmacies. As of 2026, finding Palforzia has become critically urgent: Stallergenes Greer is winding down commercialization with a final date of July 31, 2026. Remaining inventory is concentrated at specialty pharmacy networks and is limited.
Standard pharmacy lookup tools do not show real-time Palforzia inventory. The most efficient way to locate remaining supply is to use medfinder — a service that calls specialty pharmacies near you and checks which ones have your specific Palforzia dose in stock. The Palforzia Pathway Patient Hub (1-844-PALFORZ) is also a critical resource for locating remaining supply and transition support.
Palforzia is not a controlled substance and carries no DEA scheduling restrictions, but it does require prescribers to be enrolled in the FDA's Palforzia REMS program. Only REMS-certified healthcare providers can prescribe Palforzia, and only REMS-certified pharmacies can dispense it. Prescribers must complete training on anaphylaxis risk management, REMS patient enrollment, and Palforzia dosing protocols before prescribing.
Types of providers who may prescribe Palforzia (if REMS-certified):
Board-certified allergists and immunologists
Pediatric allergists
Academic medical center food allergy specialists
Telehealth is not an option for Palforzia therapy — the Initial Dose Escalation and every first dose at a new up-dosing level must be administered in person at a REMS-certified healthcare setting with trained staff and emergency equipment. Use the Palforzia.com provider search or call 1-844-PALFORZ to locate a REMS-certified allergist. Note: Given the July 2026 discontinuation, new patient starts are no longer being initiated.
No. Palforzia is not a controlled substance and is not scheduled by the DEA. It does not have abuse potential or dependency risk. However, Palforzia is a prescription-only medication that can only be dispensed through the FDA's REMS (Risk Evaluation and Mitigation Strategy) program, which requires certified prescribers, enrolled healthcare settings, and certified specialty pharmacies.
The REMS program is not related to controlled substance scheduling — it exists because Palforzia can cause life-threatening anaphylaxis (a boxed warning) and requires that patients have trained prescribers, certified dispensing facilities, and injectable epinephrine available at all times. This is a safety protocol, not a restriction related to addiction or abuse potential.
Side effects are expected with Palforzia, especially during early up-dosing phases. Common side effects in patients ages 4-17 include:
Abdominal pain and stomach cramping
Nausea and vomiting
Oral pruritus (itchy mouth) and oral paresthesia (tingling)
Throat irritation and throat tightness
Cough, wheezing, rhinorrhea, sneezing
Urticaria (hives) and pruritus (skin itching)
Ear pruritus and dyspnea (shortness of breath)
Anaphylaxis (Boxed Warning): Severe, potentially life-threatening allergic reactions can occur at any time. Use epinephrine immediately and call 911.
Eosinophilic esophagitis (EoE): Inflammatory esophageal condition; symptoms include difficulty swallowing, food stuck in throat, chest pain. Discontinue Palforzia and contact allergist if EoE is suspected.
Know what you need? Skip the search.
Omalizumab (Xolair)
FDA-approved for food allergy including peanut (Feb 2024); ages 1+; injection every 2-4 weeks; covers multiple food allergens; does not require REMS certification.
Office-based peanut OIT
Non-pharmaceutical peanut flour OIT offered by many board-certified allergists; not FDA-approved; lower cost than Palforzia; similar clinical approach.
Viaskin Peanut (investigational)
DBV Technologies epicutaneous immunotherapy patch; peanut protein delivered through skin; in clinical trials, not yet FDA-approved.
Strict avoidance + epinephrine auto-injector
Standard-of-care baseline; avoid all peanut; carry EpiPen or Auvi-Q at all times; appropriate for patients who cannot or choose not to pursue immunotherapy.
Prefer Palforzia 3 mg? We can find it.
Beta-blockers (propranolol, atenolol, metoprolol)
majorCan increase anaphylaxis severity and reduce epinephrine effectiveness for treating reactions. Discuss alternative medications with prescribing physician before starting Palforzia.
ACE inhibitors (lisinopril, enalapril, ramipril)
moderateMay increase anaphylaxis risk and affect epinephrine effectiveness. Discuss with allergist and prescribing physician — alternative antihypertensives may be considered.
MAOIs (phenelzine, tranylcypromine, selegiline)
majorCan cause dangerous hypertensive crisis if epinephrine is administered to treat anaphylaxis. Rare in pediatrics but critical to disclose all psychiatric medications.
Antihistamines (cetirizine, loratadine)
minorMay be recommended by allergist to manage mild reactions during OIT. Cannot prevent anaphylaxis — never substitute for epinephrine in a severe reaction.
Immunosuppressants (corticosteroids, methotrexate, biologics)
moderateMay impair immune response to OIT desensitization process. Long-term systemic corticosteroid use may reduce efficacy of Palforzia. Discuss all immunosuppressive medications with allergist.
Palforzia represented a true milestone in food allergy medicine — the first time a food allergen was transformed into a standardized, FDA-approved prescription therapy. It proved that oral immunotherapy works, that peanut allergy desensitization is achievable for most patients, and that food OIT belongs in mainstream clinical practice. Its commercial discontinuation in July 2026 is a business outcome, not a scientific failure.
For patients currently on Palforzia, the most important step is immediate consultation with your REMS-certified allergist. Do not stop Palforzia abruptly. Explore transition options including office-based peanut OIT or omalizumab (Xolair), which was FDA-approved for food allergy in February 2024. The peanut allergy treatment landscape will continue to evolve — Palforzia's legacy will live on in the clinical evidence base and expanded pipeline it helped create.
If you need to locate remaining Palforzia supply before July 2026, medfinder can help you search specialty pharmacies near you quickly and efficiently — without spending hours on hold. Contact 1-844-PALFORZ for transition support from Stallergenes Greer.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Palforzia 3 mg. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini